Result - Financial Results
Deal
Deal value—
Deal vs businessQ1 FY27 revenue reached ₹44.68 Cr vs TTM revenue of ₹36 Cr
Execution period1.0 yr
Fundamental gradeC
AI projections
Revenue uplift (yr1 / steady)25.0% / 40.0%
EPS uplift—
Upside base / bull / bear15.0% / 45.0% / -25.0%
Horizon12-24 months
Realized market record
Entry — next-day open (14 Aug 2026)₹33.19
Latest close (16 Sep 2026)₹32.88
Return since-0.9%
α vs Smallcap 250+1.8%
Positives
- Significant operational scale-up with Q1 FY27 revenue touching ₹44.68 Cr
- High promoter equity stake of 74.5%
- Low financial leverage with D/E of 0.15
- Clear management timeline for operational breakeven by Q3 FY27
Risks
- Continued bottom-line loss of ₹0.97 Cr in Q1 FY27
- Severe margin compression due to 73% YoY rise in other expenses to ₹6.85 Cr
- Depressed return on capital employed at 3.1%
- Risk of execution delays in reaching target breakeven at Adawinekkalam plant
Full AI brief
Executive Summary
Virat Crane Industries reported Q1 FY27 revenue of ₹44.68 Cr, showing a top-line growth of 10.3% YoY. However, the company remains in a loss-making position with a net loss of ₹0.97 Cr for the quarter, primarily driven by overheads and depreciation from its new Adawinekkalam facility. Management has guided for operational breakeven by Q3 FY27. While revenue scaling is evident, underlying profitability and a low trailing ROCE (3.1%) limit near-term upside.
Ramp-Aware Financial & Valuation Impact Math
- Top-Line Dynamics: Q1 FY27 revenue of ₹44.68 Cr indicates run-rate expansion, but YoY growth was 10.3% relative to Q1 FY26 (₹40.50 Cr).
- Margin Compression: Other expenses expanded by 73% YoY to ₹6.85 Cr, resulting in an operating drag and net loss of ₹0.97 Cr (EPS -₹0.47).
- Path to Breakeven: If Adawinekkalam reaches breakeven in Q3 FY27, full-year FY28 PAT could potentially return to positive territory (target ₹3-4 Cr PAT).
- Valuation: At ₹34.2 per share (Market Cap ₹70 Cr), the stock trades at 2.5x P/B and 21x trailing P/E. Sustained upside requires actual conversion of revenue scale into positive bottom-line earnings.
Quality & Risk Assessment
- Capital Efficiency: Trailing ROCE stands at a low 3.1%, indicating significant unutilized capital or gestation lag.
- Balance Sheet Strength: Debt remains low at ₹4 Cr (D/E 0.15), providing solvency runway during the plant ramp-up.
- Promoter Alignment: High promoter ownership at 74.5% provides stability.
Conclusion & Verdict
Given current losses and execution dependency on the Q3 FY27 breakeven timeline, the stock is rated as an UNLIKELY multibagger until clear signs of operational leverage and net profitability manifest.
Analysis as of 2026-08-13 (price ₹34.21) ·
AI research, not investment advice.
FollowTelegram
